Autolus Therapeutics Gestione
Criteri Gestione verificati 3/4
Autolus Therapeutics Il CEO è Chris Itin, nominato in Mar2016, e ha un mandato di 10.25 anni. la retribuzione annua totale è $ 2.70M, composta da 25% di stipendio e 75% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.42% delle azioni della società, per un valore di $ 1.74M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.8 anni e 3 anni.
Informazioni chiave
Chris Itin
Amministratore delegato
US$2.7m
Compenso totale
| Percentuale dello stipendio del CEO | 24.98% |
| Mandato del CEO | 10.3yrs |
| Proprietà del CEO | 0.4% |
| Durata media del management | 2.8yrs |
| Durata media del Consiglio di amministrazione | 3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento della narrazione • Jun 05
AUTL: Early Demand Trends And Profit Outlook Set Up Potential Repricing
Analysts have nudged their average price target on Autolus Therapeutics to around $10, reflecting updated views on Aucatyzl U.S. demand and an early positive read on the UK launch, even as differing research opinions partly offset one another. Analyst Commentary Street research around Autolus Therapeutics is split, with bullish analysts focusing on early commercial traction for Aucatyzl and more cautious voices questioning how much of that optimism is already reflected in valuation.
Aggiornamento della narrazione • May 18
AUTL: Early Commercial Traction And Cost Actions Will Support A Brighter Outlook
Analysts have adjusted their fair value estimate for Autolus Therapeutics to $11.00 from $13.00, citing updated assumptions around revenue growth, profitability, and future P/E, along with recent shifts in Street price targets following the Q1 report and Aucatyzl launch trends in the U.S. and UK. Analyst Commentary Recent Street commentary reflects a mix of optimism and recalibration around Autolus Therapeutics, with bullish analysts pointing to early commercial trends for Aucatyzl as a key driver for their views on valuation and execution.Aggiornamento della narrazione • May 03
AUTL: Rebased Profit Assumptions Set Stage For Future Upside Execution
Analysts have reduced their price targets on Autolus Therapeutics by $2 to $3, citing updated assumptions on discount rates, profit margins, and future P/E levels that temper prior expectations. Analyst Commentary Bullish Takeaways Bullish analysts see the updated discount rates and profit margin assumptions as a reset that can make future execution milestones more impactful for valuation, rather than relying on aggressive prior models.Aggiornamento della narrazione • Apr 18
AUTL: Higher Risk Assumptions Will Still Support Upside Potential
Analysts have modestly lifted their fair value estimate for Autolus Therapeutics from $8.79 to $8.81, tying the change to updated assumptions for discount rates, revenue growth, profit margins, and future P/E, along with recent price target revisions from the Street. Analyst Commentary Recent Street research has focused on recalibrating price targets for Autolus Therapeutics, which feeds directly into the modest change in fair value.Aggiornamento della narrazione • Mar 31
AUTL: Lower 2026 Sales Guidance Will Still Support Upside Potential
Analysts have trimmed their price targets on Autolus Therapeutics by $2 to $3 following updated 2026 Aucatzyl sales guidance of $120M to $135M, as well as a recalibration of revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research notes highlight a mixed but focused view on Autolus Therapeutics, centered on execution against updated Aucatzyl sales guidance, cost structure, and how these flow through to valuation assumptions.Seeking Alpha • Mar 27
Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts
Summary Autolus Therapeutics plc maintains a Hold rating due to a challenging risk/reward profile despite strong clinical data for Aucatzyl in r/r B-ALL. 2026 guidance targets $120–$135m in product revenues and a shift to positive gross margin, with AUTL's cash runway projected into Q4 2027. Key catalysts include pediatric ALL Phase 2 data (2027) and initial MS autoimmune data (late 2026), both with significant upside potential. Competitive pressures, funding needs beyond 2027, and uncertain commercial uptake in cell therapy remain material risks for AUTL. Read the full article on Seeking AlphaArticolo di analisi • Feb 03
The Market Doesn't Like What It Sees From Autolus Therapeutics plc's (NASDAQ:AUTL) Revenues Yet As Shares Tumble 26%
Autolus Therapeutics plc ( NASDAQ:AUTL ) shareholders won't be pleased to see that the share price has had a very rough...Articolo di analisi • Dec 20
Autolus Therapeutics plc's (NASDAQ:AUTL) Shares Bounce 28% But Its Business Still Trails The Industry
Autolus Therapeutics plc ( NASDAQ:AUTL ) shares have had a really impressive month, gaining 28% after a shaky period...Nuova narrazione • Aug 17
Robust Clinical Uptake Will Expand Advanced Cancer Therapy Adoption
Key Takeaways Accelerating adoption, regulatory progress, and expanded clinical indications position Autolus for increased market share and long-term revenue growth in advanced cancer therapies. Improved manufacturing efficiency and financial discipline strengthen margins, enabling investment in innovation and geographic expansion while supporting sustained profitability.Articolo di analisi • Apr 04
Industry Analysts Just Upgraded Their Autolus Therapeutics plc (NASDAQ:AUTL) Revenue Forecasts By 12%
Celebrations may be in order for Autolus Therapeutics plc ( NASDAQ:AUTL ) shareholders, with the analysts delivering a...Seeking Alpha • Mar 04
Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy
Summary Autolus Therapeutics' main focus is on obe-cel, a CAR T-cell therapy for B-cell ALL, with a strong likelihood of approval. AUTL has $657.1 million in cash, providing a cash runway of approximately 3 years, alleviating immediate financial concerns. The company faces significant competition in the CD19 CAR T-cell therapy market, making sales execution crucial for success. Despite the competitive landscape, AUTL's broad pipeline and recent approval of obe-cel position it well for future growth. Read the full article on Seeking AlphaSeeking Alpha • Feb 05
Autolus Therapeutics Will Remain Depressed For A While
Summary Autolus Therapeutics' obe-cel, branded Aucatzyl, is the first CAR-T therapy approved without a REMS, highlighting its safety and unique mechanism. Despite initial stock surge post-approval, AUTL's stock has steadily declined due to market skepticism on CAR-T's financial efficiency and pre-approval fundraising. AUTL's financials show a strong cash position but poor market performance, with the stock trading below cash value, excluding debt. The market demands sustained earnings and cautious fund-raising, suggesting AUTL's stock will remain depressed for the next 3-4 years. Read the full article on Seeking AlphaArticolo di analisi • Jan 07
Is Autolus Therapeutics (NASDAQ:AUTL) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Nov 21
AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market
Summary Autolus Therapeutics' AUCATZYL, approved by the FDA for relapsed/refractory B-cell ALL, shows strong potential despite safety concerns. The Company’s Obe-cel family and oncology pipeline include multiple catalysts for 2025, expanding potential indications in autoimmune diseases and hematologic malignancies. AUTL's cash runway of 1.9 years and no financial debt provide a solid financial foundation to support AUCATZYL's commercialization and future growth. Key risks include scaling manufacturing, securing insurance coverage, and expanding treatment centers, but these are manageable, supporting a bullish long-term outlook. Autolus's valuation appears undervalued given AUCATZYL's market potential and robust pipeline, including multiple CAR T-cell therapies in various trial stages. Read the full article on Seeking AlphaSeeking Alpha • Sep 06
Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case
Summary Autolus Therapeutics plc has a PDUFA date upcoming for its cell therapy obe-cel, indicated for B-ALL. The FDA will decide whether to approve the drug for commercial use. There is already a cell therapy approved in this indication, as well as Amgen's blincyto, but obe-cel's safety and efficacy profile appears strong. Autolus has taken its time gathering the data required to push for approval, but now it has US and EU approval in its sights. An intriguing secondary catalyst is obe-cel in autoimmune disease systemic lupus erythematosus - positive data could send the share price soaring. I have followed Autolus for some time, and my “buy” calls have not come off — but I remain optimistic there is a cell therapy player of note here and I am keeping the faith. Read the full article on Seeking AlphaArticolo di analisi • Aug 15
Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Jul 31
Autolus Therapeutics: Major Inflection Point On The Horizon
Summary Today, we are putting T cell developmental firm Autolus Therapeutics plc back in the spotlight for the first time in a year and a half. The company could garner its first FDA approval later this year, and recently signed an enhanced partnership arrangement with a large player in the biotech space. An updated analysis around Autolus Therapeutics follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • May 14
Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity
Summary Autolus Therapeutics now has years of operational runway after recent financing. Operating expenses are manageable, with numerous pipeline projects in the hopper. Autolus likely has an approved therapy on their hands, just waiting for the November action date to realize it. Read the full article on Seeking AlphaArticolo di analisi • Nov 06
We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Articolo di analisi • Jun 26
Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$289m |
| Dec 31 2025 | US$3m | US$674k | -US$288m |
| Sep 30 2025 | n/a | n/a | -US$225m |
| Jun 30 2025 | n/a | n/a | -US$228m |
| Mar 31 2025 | n/a | n/a | -US$238m |
| Dec 31 2024 | US$2m | US$595k | -US$221m |
| Sep 30 2024 | n/a | n/a | -US$270m |
| Jun 30 2024 | n/a | n/a | -US$234m |
| Mar 31 2024 | n/a | n/a | -US$221m |
| Dec 31 2023 | US$2m | US$551k | -US$208m |
| Sep 30 2023 | n/a | n/a | -US$158m |
| Jun 30 2023 | n/a | n/a | -US$155m |
| Mar 31 2023 | n/a | n/a | -US$152m |
| Dec 31 2022 | US$3m | US$502k | -US$149m |
| Sep 30 2022 | n/a | n/a | -US$164m |
| Jun 30 2022 | n/a | n/a | -US$155m |
| Mar 31 2022 | n/a | n/a | -US$146m |
| Dec 31 2021 | US$3m | US$543k | -US$142m |
| Sep 30 2021 | n/a | n/a | -US$143m |
| Jun 30 2021 | n/a | n/a | -US$147m |
| Mar 31 2021 | n/a | n/a | -US$145m |
| Dec 31 2020 | US$4m | US$522k | -US$142m |
| Sep 30 2020 | n/a | n/a | -US$140m |
| Jun 30 2020 | n/a | n/a | -US$130m |
| Mar 31 2020 | n/a | n/a | -US$127m |
| Dec 31 2019 | US$5m | US$517k | -US$124m |
Compensazione vs Mercato: La retribuzione totale di Chris ($USD 2.70M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 2.48M ).
Compensazione vs guadagni: La retribuzione di Chris è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Chris Itin (62 yo)
10.3yrs
Mandato
US$2,698,699
Compensazione
Dr. Christian Martin Itin, also known as Chris, Ph D., has been the Chief Executive Officer of Autolus Therapeutics Plc. (Former Name: Autolus Limited) since March 3, 2016.Dr. Itin has been Director of Au...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 10.3yrs | US$2.70m | 0.42% $ 1.7m | |
| Founder | 11.8yrs | Nessun dato | 0% $ 0 | |
| Senior VP & CFO | 2.8yrs | Nessun dato | 0% $ 0 | |
| Senior VP & COO | 9.7yrs | Nessun dato | 0.072% $ 299.8k | |
| Senior VP of Finance | less than a year | Nessun dato | Nessun dato | |
| Senior VP & Chief Technology Officer | less than a year | Nessun dato | 0.0089% $ 37.0k | |
| Senior VP of Legal Affairs & General Counsel and Secretary | 4.7yrs | Nessun dato | 0.0069% $ 28.7k | |
| Senior VP & Chief Human Resources Officer | 4.7yrs | Nessun dato | 0% $ 0 | |
| Senior VP & Chief Business Development Officer | 2.4yrs | Nessun dato | 0.0031% $ 12.8k | |
| Senior VP & Chief Development Officer | 1.8yrs | Nessun dato | Nessun dato | |
| Senior VP | less than a year | Nessun dato | Nessun dato | |
| Director of Investor Relations | no data | Nessun dato | Nessun dato |
2.8yrs
Durata media
53yo
Età media
Gestione esperta: Il team dirigenziale di AUTL è considerato esperto (durata media dell'incarico 2.8 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 11.7yrs | US$2.70m | 0.42% $ 1.7m | |
| Independent Non-Executive Director | 4.6yrs | US$201.61k | 0% $ 0 | |
| Independent Chairman of the Board | 2.2yrs | US$372.57k | 0% $ 0 | |
| Independent Non-Executive Director | 8yrs | US$200.48k | 0.0038% $ 15.6k | |
| Independent Non-Executive Director | 11.8yrs | US$198.46k | 0.051% $ 212.7k | |
| Independent Non-Executive Director | 8yrs | US$207.90k | 0% $ 0 | |
| Independent Non-Executive Director | 2.4yrs | US$297.60k | 0% $ 0 | |
| Independent Non-Executive Director | 3yrs | US$198.91k | 0% $ 0 | |
| Independent Director | 1.4yrs | US$13.45k | Nessun dato | |
| Independent Non-Executive Director | 2.2yrs | US$292.94k | 0% $ 0 | |
| Independent Non-Executive Director | 2.5yrs | US$269.16k | 0% $ 0 |
3.0yrs
Durata media
59yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AUTL sono considerati esperti (durata media dell'incarico 3 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/15 13:20 |
| Prezzo dell'azione a fine giornata | 2026/06/15 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Autolus Therapeutics plc è coperta da 17 analisti. 9 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| James Shin | Deutsche Bank |
| Rajan Sharma | Goldman Sachs |
| Emily Bodnar | H.C. Wainwright & Co. |